NCT05351437View on ClinicalTrials.gov

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

September 4, 2022

Study Completion Date

November 2, 2022

Conditions

SARS-CoV-2 Infection

Interventions

DRUG

MTx-COVAB36

MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.

DRUG

Placebo

0.9% saline

Trial Locations (1)

6009

Linear Clinical Research, Nedlands